1366 B7-H3xCD3 bispecific antibody as novel treatment option in HER2-negative breast cancer

Ítems similars

• Targeting CD276 for T cell-based immunotherapy of breast cancer
  per: Ilona Hagelstein, et al.
  Publicat: (2024-10-01)
• Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)
  per: Susanne Jung, et al.
  Publicat: (2024-02-01)
• 1366 B7-H3xCD3 bispecific antibody as novel treatment option in HER2-negative breast cancer
  per: Ilona Hagelstein, et al.
  Publicat: (2023-11-01)
• B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer
  per: Kielbik A, et al.
  Publicat: (2026-05-01)
• The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas
  per: Samuel J. Holzmayer, et al.
  Publicat: (2024-05-01)